Trial Profile
Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 10 Dec 2022 Results(n=66) assessing Systemic immune response to Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC presented at the 45th Annual San Antonio Breast Cancer Symposium
- 29 Jul 2022 Results (n=21) assessing clinical outcomes by race among african american women with stage I-III triple-negative breast cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology